Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-II: Vididencel in AML Remission with MRD
NCT03697707Phase 2Active, not recruiting
- Sponsor
- Mendus
- Start
- Oct 2018
- Primary completion
- Mar 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 5
01
Overview
A Phase 2 trial of vididencel in acute myeloid leukemia (AML), sponsored by Mendus. Started Oct 2018; status: active, not recruiting.
02
Drugs
vididencel
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03697707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697707.